IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline November 14, 2024 Read More »
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies November 6, 2024 Read More »
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1 October 17, 2024 Read More »
IGC Pharma Wins 2 Awards in Phase 1 of NIA’S AI PREPARE Challenge, Advancing Alzheimer’s Early Prediction Research October 17, 2024 Read More »
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer’s Treatment September 18, 2024 Read More »
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer’s Disease September 4, 2024 Read More »
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer’s Disease August 22, 2024 Read More »
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist August 20, 2024 Read More »
